CDH1 and colorectal carcinoma: However, treatment with an Src kinase inhibitor inhibits tumor formation by the CRC cells in vivo and upregulates the expression of E-cadherin and α-catenin, which promotes strong cell–cell adhesion and morphological changes [124,125].